GAITHERSBURG, MD — January 04, 2021 – NexImmune, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced the hiring of veteran biopharmaceutical industry leader Jerome (Jerry) Zeldis, MD, PhD, as Executive Vice President of Research & Development and the appointment of leading immunotherapy expert Jeffrey Weber, MD, PhD, as Chief Scientific Advisor and Scientific Advisory Board Chair.
{iframe}https://www.neximmune.com/neximmune-strengthens-scientific-leadershop-by-appointing-jerom-zeldis-as-evp-r-and-d-andjeffery-weber-as-chief-scientific-advisor.html{/iframe}